Search - tctmd.com

Displaying 21 - 40 of 177

Sort: Relevancy | Date

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

News Conference News TCT 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

October 31, 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

March 05, 2023

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

News Conference News AHA 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

November 10, 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

News Conference News EACTS 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

October 12, 2022

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

News Conference News TCT 2022

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

Yael L. Maxwell

September 27, 2022

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

News Conference News TCT 2022

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

September 22, 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

News Conference News ACC 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

April 02, 2022

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

News Conference News AHA 2021

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Michael O'Riordan

November 15, 2021

Cardiogenic Shock: SCAI Categories Get a Rethink as Research Rolls On

News Conference News TCT 2021

Cardiogenic Shock: SCAI Categories Get a Rethink as Research Rolls On

November 09, 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

News Conference News TCT 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

November 04, 2021

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

August 30, 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

News Conference News EuroPCR 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

Michael O'Riordan

May 18, 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

Cardiogenic Shock: Protocols, Clear Definitions Advance the Field

News Conference News SCAI 2021

Cardiogenic Shock: Protocols, Clear Definitions Advance the Field

April 30, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.